Italy Diabetes Care Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Italy Diabetes Care Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Italy diabetes care devices market is expected to reach USD 1.2 billion by 2027, registering a CAGR of more than 7% from 2022 to 2027.

Within the first year since its inception, the COVID-19 pandemic has been responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy is among the countries with the highest excess mortality. Most people who have died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

The COVID-19 pandemic has significantly impacted Italy’s diabetes care devices. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the diabetes care device market's growth.

About 9.9% of the Italian population has diabetes as of 2021. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic care products. In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsContinuous Glucose Monitoring Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period

Continuous Glucose Monitoring Segment recorded more than USD 455 million in revenue in 2021, which is expected to further increase with a CAGR of more than 12% during the forecast period.

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly.

The Italian National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need. Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery. The Italian health system is highly decentralized, with most administrative and organizational powers held by the Regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care, with a patient-centered focus.

The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. These technologies overcome many of the limitations of self-monitoring of blood glucose (SMBG) by fingerprick and allow to go beyond HbA1c to check glucose control in diabetes. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. The continuous glucose monitoring (CGM) sensors have opened new scenarios to assess, off-line, the effectiveness of individual patient therapeutic plans and stimulated the development of innovative online applications, such as hypo/hyperglycemia alert systems and artificial pancreas closed-loop control algorithms. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies.

The increased diabetic prevalence in Italy and the aforementioned factors are likely to drive the segment growth during the forecast period.

Insulin Disposable pens Occupied the Highest Share in the Management Devices Segment in 2021

Insulin Disposable pens occupied the highest market share of more than 54% in the management devices segment in 2021.

An insulin disposable pen contains a prefilled amount of insulin, when the pen is empty, it is thrown away. Insulin pens are much smaller and more portable than syringes and have the medicine preloaded into the delivery mechanism. The needles are easy to use and can be disposed of by twisting or snapping after use. The pens are usually color-coded which makes it easier to know which type of insulin and how much insulin will be received from them. The insulin disposable pens are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Some pens are ‘smart insulin pens’ which easily connect to an app on phone to monitor blood sugar levels and remind when to take the next insulin dose.

The increase in the use of disposable pens is also due to the recent pandemic, which has stimulated the growth of telemedical solutions and digital health, to decrease the influx of patients in hospitals and thus stem the spread of the virus. Another reason that has led to the growth of this type of market in Italy is the increase in the number of people with diabetes each year. Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS offers to citizens, with or without partial contributions based on a patient's income. The Insulin pens are free of cost for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.

Technological development is gaining momentum in the insulin devices market. Over the years, in fact, several technological innovations have been developed that have led to the creation of new types of devices that are more comfortable for patients compared to the traditional ones. Such advantages have helped the rise in the adoption of these products in the Italian market.

Competitive Landscape

The Italian diabetes care devices market has been driven by manufacturers like Roche, Abbott, Novo Nordisk, Dexcom, and Medtronic to compete in the market. The major companies are partnering with each other to develop new technologies in diabetes care devices, which is likely to drive the market in the future. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.